Clinical trial · Interventional
Access to Genetic Testing in Underserved Patients With Cancer
Increasing Access to Genetic Testing in Underserved Patients Using a Multilingual Conversational Agent
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider. Patients with cancer are increasingly recommended for genetic testing as standard of care. Multiple factors contribute to low usage of genetic testing but for many patients the lack of access to genetic counseling and testing is an important and flexible factor. Lack of access is especially relevant to racial/ethnic minority patients and those living in non-metropolitan rural settings who are frequently cared for at safety-net hospitals with limited genetics services. Alternative delivery models are necessary to improve rates of access to genetic testing in patients with cancer. Health information technology is under used by genetics providers. A patient-facing relational agent (PERLA) will provide pre-test genetics education in both English and Spanish across two clinical settings to facilitate more timely access to genetic testing. Using the PERLA intervention may help researchers learn different ways to provide education about genetic testing to patients with cancer compared to usual care.
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Carcinoma | Breast Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Male Breast Carcinoma | Male Breast Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Malignant Solid Neoplasm | Malignant Solid Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Metastatic Prostate Carcinoma | Prostate Carcinoma | CURATED_BROADER | 0.78 |
| Ovarian Carcinoma | Ovarian Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Pancreatic Exocrine Neoplasm | Pancreatic Exocrine Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Stage IVB Prostate Cancer American Joint Committee on Cancer v8 | — | UNRESOLVED | — |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Best Practice | Other | — | UNRESOLVED |
| Educational Intervention | Other | — | UNRESOLVED |
| Electronic Health Record Review | Other | — | UNRESOLVED |
| Genetic Counseling | Other | — | UNRESOLVED |
| Interview | Other | — | UNRESOLVED |
| Survey Administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intervention Phase Arm A (PERLA)
- description
- Patients receive access to PERLA comprising pre-test genetics education and standard post-test provider-based genetic counseling over 20-60 minutes. .
- interventionNames
- Other: Educational Intervention
- Other: Electronic Health Record Review
- Other: Genetic Counseling
- Other: Interview
- Other: Survey Administration
- type
- ACTIVE_COMPARATOR
- label
- Intervention Phase Arm B (usual care)
- description
- Patients receive access to usual care pre- and post-test provider-based genetic counseling.
- interventionNames
- Other: Best Practice
- Other: Electronic Health Record Review
- Other: Survey Administration
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years old * Diagnosed with least one of the following: * Epithelial ovarian cancer * Exocrine pancreatic cancer * Metastatic or high or very high-risk prostate cancer * Breast cancer at or before age 50 * Bilateral breast cancer * Triple negative breast cancer * Male breast cancer OR * Healthcare provider who treats patients with any of the above types of cancer * Able to read and write in English or Spanish * Able to provide informed consent Exclusion Criteria: * Patients who cannot provide informed consent * Patients who cannot see, read, or write * Patients who have the cancer and clinical characteristics defined in the inclusion criteria, but who do not speak English or Spanish * Patients with none of the listed cancer diagnoses and clinical characteristics * Healthcare provider who do not treats cancer patients
References
Publications (0)
Data not yet available